Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced stage Hodgkin Lymphoma: results from the randomized international GHSG HD18 trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43926228" target="_blank" >RIV/00064173:_____/24:43926228 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11120/24:43926228

Result on the web

<a href="https://doi.org/10.1016/j.annonc.2023.11.014" target="_blank" >https://doi.org/10.1016/j.annonc.2023.11.014</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.annonc.2023.11.014" target="_blank" >10.1016/j.annonc.2023.11.014</a>

Result language

angličtina

Original language name

Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced stage Hodgkin Lymphoma: results from the randomized international GHSG HD18 trial

Original language description

BACKGROUND: Persisting cancer-related fatigue impairs health related quality of life (HRQoL) and social re-integration in patients with Hodgkin lymphoma (HL). The GHSG HD18 trial established PET-2 guided treatment de-escalation for advanced-stage HL as new standard. Here, we investigate the impact of treatment de-escalation on long-term HRQoL, time-to-recovery from fatigue (TTR-F) and time-to-return to work (TTR-W). PATIENTS AND METHODS: Patients received EORTC QLQ-C30 and life situation questionnaires at baseline, interim, end-of-treatment, and yearly follow-up. TTR-F was defined as time from end of chemotherapy until the first fatigue score &lt; 30. TTR-W was analyzed in previously working or studying patients and measured from end of treatment until first documented work or education. We compared duration of treatment on TTR-F and TTR-W using Cox proportional hazards regression adjusted for confounding variables. RESULTS: HRQoL questionnaires at baseline were available in 1632 (83.9%) of all randomized patients. Overall, higher baseline fatigue and age were significantly associated with longer TTR-F and TTR-W and male sex with shorter TTR-W. Treatment reduction from eight to four chemotherapy cycles led to a significantly shorter TTR-F (HR 1.41, p=0.008) and descriptively shorter TTR-W (HR 1.24, p=0.084) in PET-2 negative patients. Reduction from six to four cycles led to non-significant but plausible intermediate accelerations. Addition of Rituximab caused significantly slower TTR-F (HR 0.70, p=0.0163) and TTR-W (HR 0.64, p = 0.0017) in PET-2 positive patients. HRQoL at baseline and age were the main determinants of 2y HRQoL. CONCLUSIONS: Individualized first-line treatment in patients with advanced-stage HL considerably shortens TTR-F and TTR-W in PET-2 negative patients. Our results support the use of response-adapted shortened treatment duration for patients with HL.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Annals of Oncology

ISSN

0923-7534

e-ISSN

1569-8041

Volume of the periodical

35

Issue of the periodical within the volume

3

Country of publishing house

GB - UNITED KINGDOM

Number of pages

9

Pages from-to

276-284

UT code for WoS article

001198054000001

EID of the result in the Scopus database

2-s2.0-85183544403